194 related articles for article (PubMed ID: 29676481)
1. High-mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches.
Angelopoulou E; Piperi C; Papavassiliou AG
J Neurochem; 2018 Aug; 146(3):211-218. PubMed ID: 29676481
[TBL] [Abstract][Full Text] [Related]
2. High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's Disease.
Goyal A; Agrawal A; Dubey N; Verma A
Curr Pharm Biotechnol; 2024; 25(8):937-943. PubMed ID: 37670710
[TBL] [Abstract][Full Text] [Related]
3. In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.
Santoro M; Maetzler W; Stathakos P; Martin HL; Hobert MA; Rattay TW; Gasser T; Forrester JV; Berg D; Tracey KJ; Riedel G; Teismann P
Neurobiol Dis; 2016 Jul; 91():59-68. PubMed ID: 26921471
[TBL] [Abstract][Full Text] [Related]
4. Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish.
Ren Q; Jiang X; Paudel YN; Gao X; Gao D; Zhang P; Sheng W; Shang X; Liu K; Zhang X; Jin M
J Ethnopharmacol; 2022 Jun; 292():115234. PubMed ID: 35358621
[TBL] [Abstract][Full Text] [Related]
5. The Oral Pretreatment of Glycyrrhizin Prevents Surgery-Induced Cognitive Impairment in Aged Mice by Reducing Neuroinflammation and Alzheimer's-Related Pathology via HMGB1 Inhibition.
Kong ZH; Chen X; Hua HP; Liang L; Liu LJ
J Mol Neurosci; 2017 Dec; 63(3-4):385-395. PubMed ID: 29034441
[TBL] [Abstract][Full Text] [Related]
6. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches.
Paudel YN; Semple BD; Jones NC; Othman I; Shaikh MF
J Neurochem; 2019 Dec; 151(5):542-557. PubMed ID: 30644560
[TBL] [Abstract][Full Text] [Related]
7. Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease.
Sato F; Nakamura Y; Ma S; Kochi T; Hisaoka-Nakashima K; Wang D; Liu K; Wake H; Nishibori M; Morioka N
Biomed Pharmacother; 2022 Jan; 145():112479. PubMed ID: 34915668
[TBL] [Abstract][Full Text] [Related]
8. Involvement of high mobility group box-1 in imiquimod-induced psoriasis-like mice model.
Chen T; Fu LX; Guo ZP; Yin B; Cao N; Qin S
J Dermatol; 2017 May; 44(5):573-581. PubMed ID: 27943400
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling.
Li C; Peng S; Liu X; Han C; Wang X; Jin T; Liu S; Wang W; Xie X; He X; Zhang H; Shan L; Fan C; Shan Z; Teng W
Thyroid; 2017 May; 27(5):722-731. PubMed ID: 28363255
[TBL] [Abstract][Full Text] [Related]
10. Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis.
Li X; Yue Y; Zhu Y; Xiong S
Mol Immunol; 2015 May; 65(1):177-88. PubMed ID: 25660970
[TBL] [Abstract][Full Text] [Related]
11. Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease.
Sasaki T; Liu K; Agari T; Yasuhara T; Morimoto J; Okazaki M; Takeuchi H; Toyoshima A; Sasada S; Shinko A; Kondo A; Kameda M; Miyazaki I; Asanuma M; Borlongan CV; Nishibori M; Date I
Exp Neurol; 2016 Jan; 275 Pt 1():220-31. PubMed ID: 26555088
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells.
Chen X; Fang D; Li L; Chen L; Li Q; Gong F; Fang M
Immunol Res; 2017 Jun; 65(3):666-680. PubMed ID: 28108937
[TBL] [Abstract][Full Text] [Related]
13. High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior.
Wu TY; Liu L; Zhang W; Zhang Y; Liu YZ; Shen XL; Gong H; Yang YY; Bi XY; Jiang CL; Wang YX
J Psychiatr Res; 2015 May; 64():99-106. PubMed ID: 25795092
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhizin protects against focal cerebral ischemia via inhibition of T cell activity and HMGB1-mediated mechanisms.
Xiong X; Gu L; Wang Y; Luo Y; Zhang H; Lee J; Krams S; Zhu S; Zhao H
J Neuroinflammation; 2016 Sep; 13(1):241. PubMed ID: 27609334
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizin ameliorates atopic dermatitis-like symptoms through inhibition of HMGB1.
Wang Y; Zhang Y; Peng G; Han X
Int Immunopharmacol; 2018 Jul; 60():9-17. PubMed ID: 29702284
[TBL] [Abstract][Full Text] [Related]
16. Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders.
Paudel YN; Angelopoulou E; Semple B; Piperi C; Othman I; Shaikh MF
ACS Chem Neurosci; 2020 Feb; 11(4):485-500. PubMed ID: 31972087
[TBL] [Abstract][Full Text] [Related]
17. Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells.
Wang K; Huang J; Xie W; Huang L; Zhong C; Chen Z
Diagn Pathol; 2016 Jan; 11():15. PubMed ID: 26822891
[TBL] [Abstract][Full Text] [Related]
18. Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism.
Gu XJ; Xu J; Ma BY; Chen G; Gu PY; Wei D; Hu WX
Chin J Traumatol; 2014; 17(1):1-7. PubMed ID: 24506915
[TBL] [Abstract][Full Text] [Related]
19. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
[TBL] [Abstract][Full Text] [Related]
20. Postoperative impairment of cognitive function in old mice: a possible role for neuroinflammation mediated by HMGB1, S100B, and RAGE.
Li RL; Zhang ZZ; Peng M; Wu Y; Zhang JJ; Wang CY; Wang YL
J Surg Res; 2013 Dec; 185(2):815-24. PubMed ID: 23899512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
